List of Figures
Figure 1: Industry Survey Results, Therapy Areas with Highest Genericization, 2016–2021 10
Figure 2: Industry Survey Results, Therapy Areas with Highest Genericization, R&D Expert Panel vs Commercial Expert Panel, 2016–2021 11
Figure 3: Industry Survey Results, Most Important Factors Promoting Generic Drug Usage Globally 13
Figure 4: Industry Survey Results, Most Important Factors Promoting Generic Drugs Usage at a Global Level, R&D Expert Panel vs Commercial Expert Panel 14
Figure 5: Industry Survey Results, Most Important Factors Promoting Generic Drugs Usage at a Global Level, European Panel vs North American Panel vs Asia Panel 15
Figure 6: ANDAs Filed and Approved by FDA, 2008–2014 17
Figure 7: Industry Survey Results, Leading Emerging Markets for Generic Drug Manufacturers, 2016–2021 18
Figure 8: Industry Survey Results, Most Important Factors Hindering or Delaying Approval of Generic Drugs Globally 19
Figure 9: Industry Survey Results, Most Important Factors Hindering or Delaying Approval of Generic Drugs, R&D Expert Panel vs Commercial Expert Panel 20
Figure 10: Industry Survey Results, Do Physicians in Developed Markets Regard Generic Drugs to be as Safe and Effective as Branded Drugs? (%) 22
Figure 11: Sensipar, Global Revenue ($m), 2011–2021 25
Figure 12: Tarceva, Global Revenue ($m), 2011–2021 26
Figure 13: Lyrica, Global Revenue ($m), 2011–2021 27
Figure 14: Vesicare, Global Revenue ($m), 2011???2021 29
Figure 15: Viagra, Global Revenue ($m), 2011–2021 30
Figure 16: Vytorin, Global Revenue ($m), 2011–2021 31
Figure 17: Truvada, Global Revenue ($m), 2011–2021 32
Figure 18: Zytiga, Global Revenue ($m), 2011–2021 33
Figure 19: Benicar*, Global Revenue ($m), 2011–2021 34
Figure 20: Exjade, Global Revenue ($m), 2011–2021 35
Figure 21: GBI Industry Survey, Most Popular Strategies or Regulations Leveraged by Companies in Generic Sector 36
Figure 22: GBI Industry Survey, Most Popular Strategies or Regulations Leveraged by Companies in Generics Sector, North American Panel vs European Panel vs Asian Panel 37
Figure 23: GBI Industry Survey, Impact of Compulsory Licensing on Innovator Companies in Emerging Markets 43
Figure 24: GBI Industry Survey, Impact of Compulsory Licensing on Innovator Companies in Emerging Markets, North American Panel vs European Panel vs Asian Panel 44
Figure 25: GBI Industry Survey, Most Important Factors Contributing to Surge in M&A Activity in Generic Drugs Market 50
Figure 26: GBI Industry Survey, Most Important Factors Contributing to Surge in M&A Activity in Generic Drugs Market, North American Panel vs European Panel vs Asian Panel 51
Figure 27: GBI Industry Survey, Market Dynamics Affected by Continued Consolidation in Generics Market 55
Figure 28: GBI Industry Survey Results, Market Dynamics Affected By Continued Consolidation in Generics Market, North American Panel vs European Panel vs Asian Panel 56
Figure 29: Industry Survey Results, Therapy Areas with Highest Levels of Genericization, 2016–2021 67
Figure 30: Industry Survey Results, Therapy Areas with Highest Levels of Genericization, R&D Expert Panel vs Commercial Expert Panel, 2016–2021 67
Figure 31: Industry Survey Results, Most Important Factors Promoting Generic Drugs Usage at a Global Level 68
Figure 32: Industry Survey Results, Most Important Factors Promoting Generic Drugs Usage at a Global Level, R&D Expert Panel vs Commercial Expert Panel 68
Figure 33: Industry Survey Results, Most Important Factors Promoting Generic Drugs Usage at a Global Level, European Panel vs North American Panel vs Asia Panel 69
Figure 34: Industry Survey Results, Leading Emerging Markets for Generic Drug Manufacturers, 2016–2021 69
Figure 35: Industry Survey Results: Most Important Factors Hindering or Delaying Approval of Generic Drugs Globally 70
Figure 36: Industry Survey Results: Most Important Factors Hindering or Delaying Approval of Generic Drugs, R&D Expert Panel vs Commercial Expert Panel 70
Figure 37: Industry Survey Results: Do Physicians in Developed Markets Regard Generic Drugs to be as Safe and Effective as Branded Drugs? 71
Figure 38: Industry Survey results, Most Popular Strategies or Regulations Leveraged by Companies in Generic Sector 71
Figure 39: Industry Survey results, Most Popular Strategies or Regulations Leveraged by Companies in Generics Sector, North American Panel vs European Panel vs Asian Panel 72
Figure 40: Industry Survey results: The impact of compulsory licensing on innovator companies in emerging markets 72
Figure 41: GBI Industry Survey results: The impact of compulsory licensing on innovator companies in emerging markets, North American panel vs. European panel vs. Asian panel 73
Figure 42: GBI Industry Survey results: The most important factors contributing towards the surge in M&A activity within the generic drugs market 73
Figure 43: GBI Industry Survey results: Most Important Factors Contributing to Surge in M&A Activity in Generic Drugs Market, North American Panel vs European Panel vs Asian Panel 74
Figure 44: GBI Industry Survey Results: Market dynamics affected by continued consolidation in the generic drugs market 74
Figure 45: GBI Industry Survey Results, North American Panel vs European Panel vs Asian Panel, Market Dynamics Affected by Continued Consolidation in the Generic Drugs Market 75